Contact
Please use this form to send email to PR contact of this press release:
Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
TO:
Please use this form to send email to PR contact of this press release:
Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
TO: